engleski

Duodenocutaneous fistula in rats as a model for "wound healing-therapy" in ulcer healing: the effect of pentadecapeptide BPC 157, L-nitro- arginine methyl ester and L-arginine.

While very rarely reported, duodenocutanenous fistula research might alter the duodenal ulcer disease background and therapy. Our research focused on rat duodenocutaneous fistulas, therapy, stable gastric pentadecapeptide BPC 157, an anti- ulcer peptide that healed other fistulas, nitric oxide synthase-substrate L- arginine, and nitric oxide synthaseinhibitor L- nitro-arginine methyl ester (L-NAME). The hypothesis was, duodenal ulcer-healing, like the skin ulcer, using the successful BPC 157, with nitric oxide- system involvement, the “wound healing- therapy”, to heal the duodenal ulcer, the fistula-model that recently highlighted gastric and skin ulcer healing. Pressure in the lower esophageal and pyloric sphincters was simultaneously assessed. Duodenocutaneous fistula-rats received BPC 157 (10 µg/kg or 10 ng/kg, intraperitoneally or perorally (in drinking water)), L-NAME (5 mg/kg intraperitoneally), L- arginine (100 mg/kg intraperitoneally) alone and/or together, throughout 21 days. Duodenocutaneous fistula- rats maintained persistent defects, continuous fistula leakage, sphincter failure, mortality rate at 40% until the 4th day, all fully counteracted in all BPC 157-rats. The BPC 157- rats experienced rapidly improved complete presentation (maximal volume instilled already at 7th day). L-NAME further aggravated the duodenocutaneous fistula- course (mortality at 70% until the 4th day) ; L- arginine was beneficial (no mortality ; however, maximal volume instilled not before 21th day). L- NAME- worsening was counteracted to the control level with the L-arginine effect, and vice versa, while BPC 157 annulled the L-NAME effects (L- NAME + L-arginine ; L-NAME + BPC 157 ; L-NAME + L- arginine + BPC 157 brought below the level of the control). It is likely that duodenocutaneous fistulas, duodenal/skin defect simultaneous healing, reinstated sphincter function, are a new nitric oxide-system related phenomenon. In conclusion, resolving the duodenocutanenous fistulashealing, nitric oxide-system involvement, should illustrate further wound healing therapy to heal duodenal ulcers

stable gastric pentadecapeptide ; duodenocutanenous fistula ; nitric oxide ; wound healing ; nitric oxide synthase inhibitor ; L-arginine

nije evidentirano